Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cancer Control. 2023 Jan-Dec;30:10732748231199647. doi: 10.1177/10732748231199647.
Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid carcinoma, and Hashimoto's thyroiditis (HT) has been postulated to have a relationship with PTC. This study aims to assess clinical and pathological characteristics of patients with papillary thyroid carcinoma coexisting with Hashimoto's thyroiditis.
A retrospective study was conducted in a cohort of patients with thyroid carcinoma at the Department of Surgery, Shanghai General Hospital from January 2017 to December 2018. Medical records of patients who had PTC with or without HT were reviewed and clinical and histopathological characteristics of these patients were analyzed.
A total of 632 patients with thyroid carcinoma were identified. Among them, 614 (97.15%) had PTC and 120/614 (19.0%) harbored PTC together with HT. PTC was significantly associated with HT, as compared with other histological subtypes ( < .001). Patients with coexisting PTC and HT (PTC + HT group) were significantly younger than patients with PTC alone (PTC group) ( = .008). There were more women in the PTC + HT group than in the PTC group (88.3% vs. 73.1%, < .001). TSH, TGAb, and TPOAb levels were significantly higher in the PTC + HT group than in the PTC group ( ≤ .001). In addition, tumor diameter was smaller in the PTC + HT group than in the PTC group ( = .034). The PTC + HT group showed a significant better recurrence-free survival than the PTC group. Furthermore, immunohistochemical analysis revealed that patients in the PTC + HT group had a higher positive rate and higher expression intensity of Ki67 than patients in the PTC group.
Our study revealed that patients with coexisting PTC and HT were younger, had smaller tumor diameters, a better prognosis, and higher positive rates and expression intensity of Ki67, than did patients with PTC alone.
甲状腺乳头状癌（PTC）是最常见的甲状腺癌亚型，桥本甲状腺炎（HT）被认为与 PTC 有关。本研究旨在评估同时患有甲状腺乳头状癌和桥本甲状腺炎的患者的临床和病理特征。
对 2017 年 1 月至 2018 年 12 月在上海交通大学附属第一人民医院外科就诊的甲状腺癌患者进行回顾性队列研究。回顾性分析了同时患有 PTC 和 HT（PTC+HT 组）及单纯患有 PTC（PTC 组）患者的临床和组织病理学特征。
共纳入 632 例甲状腺癌患者，其中 614 例（97.15%）患有 PTC，120/614 例（19.0%）合并 PTC 和 HT。与其他组织学类型相比，PTC 与 HT 显著相关（<0.001）。合并 PTC 和 HT（PTC+HT 组）的患者显著比单纯患有 PTC（PTC 组）的患者年轻（=0.008）。PTC+HT 组的女性比例显著高于 PTC 组（88.3%比 73.1%，<0.001）。PTC+HT 组的 TSH、TGAb 和 TPOAb 水平显著高于 PTC 组（≤0.001）。此外，PTC+HT 组的肿瘤直径显著小于 PTC 组（=0.034）。PTC+HT 组的无复发生存率显著优于 PTC 组。此外，免疫组化分析显示，PTC+HT 组患者的 Ki67 阳性率和表达强度显著高于 PTC 组患者。
本研究表明，与单纯患有 PTC 的患者相比，同时患有 PTC 和 HT 的患者更年轻，肿瘤直径更小，预后更好，Ki67 的阳性率和表达强度更高。
